

## Tocilizumab (Actemra) Criteria for Use in COVID-19

---

### Inclusion Criteria:

1. Persistent febrile illness
2. Rapidly worsening gas exchange presenting as one of the following:
  - a. Requiring  $> 6$  L/min of oxygen (non-vented)
  - b.  $\text{PaO}_2/\text{FiO}_2 < 200$  (vented)
3. Absence of systemic bacterial and fungal co-infection
4. One of the following lab abnormalities
  - a. Ferritin  $> 300$  ng/mL with doubling in 24 hours
  - b. Ferritin  $> 600$  ng/mL at presentation AND LDH  $> 250$  IU/L
  - c. D-dimer  $> 1$  mcg/mL

### Exclusion Criteria:

1. AST/ALT  $> 5 \times$  ULN
2. ANC  $< 500$
3. PLT  $< 50$  K
4. Sepsis or infection from non-COVID pathogens
5. Anti-rejection immunosuppressive therapy or enrolled in baricitinib trial

### Pharmacist to Verify:

1. Positive COVID-19 PCR
2. Diagnostic codes U07.1 (Infection due to 2019 novel coronavirus) and R65.11 (SIRS due to non-infectious process with acute organ dysfunction) are present in the patient's EHR
3. Completion of patient financial screening and Genentech Foundation Enrollment Form submitted to Medication Assistance Coordinator (Jenn Pingul)
4. Consultation with ID physician to verify absence of bacterial and fungal co-infection completed
5. Followed by Pulmonary and Critical Care Medicine